인사이트
Insights From Our Experts
Articles
The Influx of Generic Launches Leaves Narrow Opportunities for Multiple Sclerosis Access
Since the launch of Sandoz’s Glatopa in June 2015, generic options have slowly entered the multiple sclerosis market, providing some cost relief to payers in this high-cost market. Generic entrants, along with rising costs and a…
Improving Patient Experience & Communication for Rare/Ultra-Rare Disease Patients by Leveraging Digital Tools
EVERSANA’s Patient Services expert, Skyler Vise, Senior Director, Client & Delivery Excellence, EVERSANA, and Ida Goldstein, Senior Director, Trade, Distribution, and Patient Services, Mirum Pharmaceutical, presented at Access USA covering how digital tools can improve the…
Patient Assistance for Gene Therapies
EVERSANA’s experts Kevin O’Meara and Skyler Vise recently took the stage at Access USA to discuss patient services solutions for patient assistance programs (PAPs) supporting cell and gene therapies. During the session, the experts explore how…
Pricing Complexities of a Combination Therapy
This article, authored by EVERSANA’s Asia Pacific team, discusses the increasing use of combination therapies in oncology and the challenges associated with pricing them. Combination therapies, which involve a backbone therapy and one or more add-on therapies,…
The IDeaS Initiative: Pilot Study to Assess the Impact of Rare Diseases on Patients and Healthcare Systems
When combined, rare diseases (RD) are not actually rare, as they collectively affect around 25–30 million people in the United States (US) and more than 300 million people worldwide. RD represent a diverse spectrum of more…
Integrating the Pillars of Global Pricing Governance
How Emerging Trends are Demanding a More Holistic View to Drive Maximum Value As the complexity of investments needed to secure patient access to therapy increases, so does the impact of these investments on a company’s…
Artificial Intelligence and Machine Learning Use in Patient Safety
The next several decades will bring increased use and advancement of technology, particularly with regard to Artificial Intelligence (AI) and Machine Learning (ML) within our personal lives and in the pharmaceutical industry. Generally, the ways…
Seven Challenges Traditional Omnichannel Tactics Cannot Overcome
How pharma companies utilize omnichannel is a significant factor in their brand’s success, especially as traditional efforts continue becoming more and more obsolete and rejected by patients and providers. Many manufacturers are facing pivotal decisions about…
The Future of Omnichannel is Here. Don’t Get Left Behind.
The standard for omnichannel continues to evolve whether pharma companies like it or not. A next-gen approach to this crucial component of the patient journey is essential to maximize success and best optimize valuable assets. In…
Create a Comprehensive Experience by Optimizing Forward-thinking Omnichannel Strategies
Deploying successful omnichannel strategies requires manufacturers to evaluate their tactics and ensure they are meeting patients’ and providers’ needs in a modern and effective way. In this article, we lay out a check list of criteria…